Using the Proteasome System to Target Artemisinin-Resistant Malaria
Presenter Type
UNO Undergraduate Student
Major/Field of Study
Biology
Other
Molecular and Biomedical Biology
Advisor Information
UNMC, Department of Pathology and Microbiology
Location
MBSC Ballroom Poster # 701 - U
Presentation Type
Poster
Start Date
24-3-2023 9:00 AM
End Date
24-3-2023 10:15 AM
Abstract
Malaria is a disease caused by a parasite transmitted through the bite of an infected mosquito. It is a substantial global health concern, with an estimated 247 million cases of Malaria worldwide and a recorded 619,000 deaths from Malaria in 2022, according to the World Health Organization (WHO). This research is about using proteasome inhibitors as a therapy for treating artemisinin-resistant Malaria. Proteasome inhibitors prevent the breakdown of proteins tagged by ubiquitin. It focuses on the P. falciparum parasite species that can be described in three stages: ring, trophozoite, and schizont. The research is vital because artemisinin resistance is becoming more prevalent since the parasites are becoming increasingly resistant to the Artemisinin-based Combination Therapies (ACTs) used to treat Malaria. Artemisinin is the most potent drug against P. falciparum, and with parasites becoming resistant, it makes treatment less effective and the disease more deadly. Additionally, this research is also critical because finding ways to fight artemisinin resistance can help aid research in fighting the significant issue of antibiotic resistance.
Scheduling
9:15-10:30 a.m., 1-2:15 p.m.
Using the Proteasome System to Target Artemisinin-Resistant Malaria
MBSC Ballroom Poster # 701 - U
Malaria is a disease caused by a parasite transmitted through the bite of an infected mosquito. It is a substantial global health concern, with an estimated 247 million cases of Malaria worldwide and a recorded 619,000 deaths from Malaria in 2022, according to the World Health Organization (WHO). This research is about using proteasome inhibitors as a therapy for treating artemisinin-resistant Malaria. Proteasome inhibitors prevent the breakdown of proteins tagged by ubiquitin. It focuses on the P. falciparum parasite species that can be described in three stages: ring, trophozoite, and schizont. The research is vital because artemisinin resistance is becoming more prevalent since the parasites are becoming increasingly resistant to the Artemisinin-based Combination Therapies (ACTs) used to treat Malaria. Artemisinin is the most potent drug against P. falciparum, and with parasites becoming resistant, it makes treatment less effective and the disease more deadly. Additionally, this research is also critical because finding ways to fight artemisinin resistance can help aid research in fighting the significant issue of antibiotic resistance.
Additional Information (Optional)
Stand for poster